Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
-
Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of...
-
CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
-
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
-
Relay Therapeutics Announces Proposed Public Offering of Common Stock
-
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
-
Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024
-
Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
-
Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024
-
Relay Therapeutics Discloses Three New Programs at New Program & Platform Event